Towards a Model-Based Dose Recommendation for Doxorubicin in Children Swantje VöllerGeorg HempelJoachim Boos Current Opinion Open access 19 September 2016 Pages: 215 - 223
Bioequivalence Evaluations of Generic Dry Powder Inhaler Drug Products: Similarities and Differences Between Japan, USA, and the European Union Ryosuke KuribayashiToru YamaguchiKazunori Takagi Review Article 26 July 2016 Pages: 225 - 233
Clinical Pharmacokinetics and Pharmacodynamics of Afatinib Sven WindDavid SchnellPeter Stopfer Review Article Open access 28 July 2016 Pages: 235 - 250
Clinical Pharmacokinetics and Pharmacodynamics of Safinamide Thomas MüllerPaul Foley Review Article 24 September 2016 Pages: 251 - 261
A Strategy for Dosing Vancomycin to Therapeutic Targets Using Only Trough Concentrations John P. Prybylski Original Research Article 07 July 2016 Pages: 263 - 272
Allometric Scaling of Clearance in Paediatric Patients: When Does the Magic of 0.75 Fade? Elisa A. M. CalvierElke H. J. KrekelsCatherijne A. J. Knibbe Original Research Article Open access 10 August 2016 Pages: 273 - 285
Imatinib Pharmacokinetics in a Large Observational Cohort of Gastrointestinal Stromal Tumour Patients Sheima FaragRemy B. VerheijenNeeltje Steeghs Original Research Article 19 July 2016 Pages: 287 - 292
Development of a Pharmacokinetic Model to Describe the Complex Pharmacokinetics of Pazopanib in Cancer Patients Huixin YuNielka van ErpAlwin D. R. Huitema Original Research Article 17 August 2016 Pages: 293 - 303
Prospective Analysis in GIST Patients on the Role of Alpha-1 Acid Glycoprotein in Imatinib Exposure Sander BinsKarel EechouteRon H. J. Mathijssen Short Communication Open access 26 July 2016 Pages: 305 - 310
Comment on: “Challenges in Individualizing Drug Dosage for Intensive Care Unit Patients: Is Augmented Renal Clearance What We Really Want to Know? Some Suggested Management Approaches and Clinical Software Tools” Johannes H. Proost Commentary 15 December 2016 Pages: 311 - 312
Author’s Reply to Proost: “Challenges in Individualizing Drug Dosage for Intensive Care Unit Patients” Roger W. Jelliffe Reply 29 December 2016 Pages: 313 - 316
